API | mirvetuximab soravtansine

mirvetuximab soravtansine Report issue

Biologics mAb ADC Orphan Drug ^FDA Approved ^FDA Fast Track ^FDA Accelerated Approval ^FDA Priority Review ^FDA

AACT ChEMBL DrugBank PubChem

Active Ingredient History

NOW

ImmunoGen, Inc. is a biotechnology company focused on the development of antibody-drug conjugate (ADC) therapeutics for the treatment of cancer. ImmunoGen was founded in 1981 and is headquartered in Waltham, Massachusetts. ^Wikipedia

Chemistry

SMILES: Missing data
InChIKey: Missing data
Mol. Mass: Missing data
ALogP: Missing data
ChEMBL Molecules:

None

mirvetuximab soravtansine

More Chemistry

Pharmacology

Mechanisms of Action:
- Folate receptor alpha (Homo sapiens) ^UniProt
Multi-specific: No
Payload: Ravtansine
Black Box: No
Availability: Missing data
Delivery Methods: Missing data
Pro Drug: No

imgn853 | imgn-853 | mirvetuximab soravtansine

Organizations (18)

Research & Development (18)

Organization	Org Type	FDA approvals	Clinical Trials involvement	Org ID	Force Sort

Marketing (0)

Organization	Org Type	FDA approvals	Clinical Trials involvement	Org ID	Force Sort

Indications (12)

Approved Indications (0)

Experimental Indications - Clinical Trial Phases 1-4 (12)

Biomarkers (Phase 2)

BRCA1 Protein (Phase 1)

Breast Neoplasms (Phase 2)

Carcinoma, Ovarian Epithelial (Phase 3)

Endometrial Neoplasms (Phase 2)

Fallopian Tube Neoplasms (Phase 3)

Fallopian Tubes (Phase 2)

Hamartoma (Phase 3)

Mutation (Phase 1)

Neoplasms (Phase 1)

Ovarian Neoplasms (Phase 3)

Uterine Neoplasms (Phase 1)

Overview

Highest Phase: Phase 3
# of Trials: 18
# of Trial Organizations: 18

Trials by Phase

Trial	Phase	Start Date	Organizations	Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue